Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
PERRIGO Co plc EVP & CBDO David Ball exercised 2,867 Restricted Stock Units into ordinary shares on June 5, 2026. As part of the same event, 1,037 ordinary shares were disposed of to cover tax obligations through a tax-withholding arrangement, a routine compensation-related transaction rather than an open-market trade.
Perrigo Company plc executive Charles Atkinson reported routine equity compensation activity involving Restricted Stock Units (RSUs). On June 5, 2026, RSUs covering 6,690 ordinary shares were exercised and converted into ordinary shares, reflecting equity granted as part of his compensation.
To cover related tax obligations, 1,835 of the resulting ordinary shares were disposed of at $10.83 per share through a tax-withholding transaction, rather than an open-market sale. Following these transactions, Atkinson holds 5,855 ordinary shares directly, and the filing shows 13,379 RSUs outstanding, each representing a contingent right to receive one ordinary share with vesting in three equal annual installments beginning June 6, 2026.
PRGO submitted a Form 144 notice reporting proposed sales of Common Stock under resale restrictions. The filing lists multiple tranches of Restricted Stock Vesting dated 05/17/2023, 05/15/2024, 05/14/2025, and 05/01/2026 with quantities 852, 4,557, 5,150, and 3,798 respectively. The cover section includes numeric entries 14357, 164242.28, and 138367770, and shows NYSE and an apparent date of 05/28/2026.
Perrigo Co plc director Geoffrey M. Parker reported multiple equity compensation transactions. On May 14 2026, he exercised 7,305 Restricted Stock Units into ordinary shares at $10.84 per share and had 3,507 shares withheld to cover tax obligations.
Following these events, Parker held 36,217 ordinary shares directly. On May 13 2026, he also received a grant of 16,681 Restricted Stock Units, each representing a contingent right to one ordinary share, with vesting stated as May 13 2027 in the footnotes.
In addition to direct holdings, the filing shows indirect ownership of ordinary shares through a Roth IRA and a revocable trust, with post-transaction balances of 17,375 shares and 25,879 shares, respectively.
Lockwood-Taylor Patrick reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc CEO Patrick Lockwood-Taylor reported an equity compensation award and updated holdings. He received 173,837 Restricted Stock Units, each representing a contingent right to one ordinary share, vesting in three equal annual installments beginning May 13, 2027. Following these transactions, he directly holds 110,846 ordinary shares of Perrigo.
Bezerra Eduardo Guarita reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc EVP & Chief Financial Officer Eduardo Guarita Bezerra reported an equity compensation grant and updated holdings. He received 52,678 Restricted Stock Units, each representing a contingent right to one ordinary share, vesting in three equal annual installments beginning on May 13, 2027. Following the reported transactions, he directly holds 77,760 ordinary shares and 52,678 Restricted Stock Units, aligning his compensation further with Perrigo’s share performance over time.
Lennox Abigail reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc executive Abigail Lennox reported an equity grant, not a stock trade. On May 13 2026, she received 31,607 Restricted Stock Units (RSUs), each representing a contingent right to one Perrigo ordinary share.
The RSUs vest in three equal annual installments beginning May 13 2027. After this filing, Lennox directly holds 2,780 ordinary shares, and the 31,607 RSUs represent additional potential shares that will be delivered only as they vest, subject to continued service and any plan conditions.
Khoury Roberto reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc executive Roberto Khoury received a compensation grant of 42,142 Restricted Stock Units on May 13, 2026. Each RSU represents a contingent right to receive one ordinary share and will vest in three equal annual installments beginning May 13, 2027. Following the transactions reported, Khoury also holds 5,205 ordinary shares directly. These awards are stock-based compensation rather than open-market share purchases or sales.
Ball David reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc executive David Ball, EVP & CBDO, reported updated holdings and a new equity award. He received a grant of 26,339 Restricted Stock Units (RSUs), each representing a contingent right to one ordinary share. These RSUs vest in three equal annual installments beginning on May 13, 2027. Following the filing, Ball directly holds 4,917 ordinary shares, separate from the RSU award.
Willis Robert reported acquisition or exercise transactions in this Form 4 filing.
Perrigo Company plc executive Robert Willis received a compensation grant of 22,388 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one ordinary share, vesting in three equal annual installments beginning on May 13, 2027.
Following the reported transactions, Willis directly holds 48,924 ordinary shares and 22,388 RSUs tied to Perrigo stock. This filing reflects an equity-based incentive award rather than an open-market purchase or sale.